American Home Products Corporation

Wyeth

Arqule, Inc.

Other

Elan Pharmaceuticals, Inc.

Dennis Michael Kubrak

John H Musser

Anthony F Kreft, Iii

Anthony Frank Kreft

George Diamantidis

Annette L Banker

Amedeo A Failli

Derek Cecil Cole

David S Casebier

Kevin R Woller

Joseph Raymond Stock

William Jay Moore

Kristina Martha Kutterer

James J Bicksler

John W Giberson

Thomas Joseph Caggiano

Charles William Mann

Eugene D Thorsett

Gary Paul Stack

Michael A Pleiss

Craig E Caufield

Darren B Dressen

James Albert Nelson

Reinhold H Bender

Uresh Shantilal Shah

Alexander A Greenfield

Boyd Lynn Harrison

Scott Christian Mayer

Koi Morris

Lynn Resnick

Molly Hoke

Diane Barbara Hauze

Alexander Michael Porte

Compounds of Formula (I), wherein R, R, R, R, R, R, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's disease and Down's syndrome are described.

Heterocyclic sulfonamide inhibitors of beta amyloid production

Compounds of Formula (I), wherein R, R, R, R, R, R, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for determining &#x3b2;-amyloid levels in a subject are described.

Heterocyclic sulfonamide inhibitors of &#x3b2; amyloid production

A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R-Rare defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors

Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Compounds of Formula (I),wherein R, R, R, R, R, R, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are described

This invention provides compounds of formula I having the structure ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are, each, independently, hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aralkoxy, trifluroalkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido;

Carbazole inhibitors of Cox-2

Pyranoindole inhibitors of COX--2

There are disclosed substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid derivatives and the pharmacologically acceptable salts thereof as inhibitors of PLA.sub.2 and lipoxygenase, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions; in the treatment of leukotriene-mediated naso-bronchial obstructive air-passageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like; and as gastric cytoprotective agents.

Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid

There are disclosed compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl;

Quinolinylmethoxy naphthalenepropionic acid derivatives as

There are disclosed compounds of the formula

Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid

There are disclosed compounds of the formula ##STR1## wherein A is alkyl of 3-19 carbon atoms, diloweralkyl allyl, dihaloallyl, diphenylallyl, lower alkynyl, ##STR2## with the proviso that A is not quinolinyl; W is --CR.sub.2 O--, --CH.dbd.CH-- or --CH.dbd.CHCH.sub.2 O--;

Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic

There are disclosed compounds of the formula ##STR1## wherein a is alkyl 3-19 carbon atoms, diloweralkyl allyl, diahaloallyl, diphenylallyl, lower alkynyl, ##STR2## W is --CR.sub.2 O--, --CH.dbd.CH-- or --CH.dbd.CHCH.sub.2 O-- X is N or CR;

Quinoline substituted naphthalenepropionic acid derivatives as

There are disclosed compounds of the formula ##STR1## wherein A is alkyl of 3-19 carbon atoms, diloweralkyl allyl, dihaloallyl, diphenylallyl, lower alkynyl, ##STR2## X is N or CR; Z is ##STR3## R is hydrogen or lower alkyl; R.sup.1 is hydrogen, lower alkyl or phenyl;

Naphthalenepropionic acid derivatives as anti-inflammatory/anti-allergic

Growing community of inventors

Philadelphia, PA, United States of America

Dennis Michael Kubrak